{"schema_version":"1.0","type":"article","title":"【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點","url":"https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.md","lang":"zh-Hant","date":"2026-05-06","publish_at":"2026-05-06T10:30:00+08:00","updated_at":"2026-05-06","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","藥華藥","生技投資"],"summary":"✨講座介紹，生技醫藥股往往囊括了市場單日最大漲幅與最大跌幅，是極具爆發力的投資領域。然而，多數人將其視為妖股，是因為缺乏一套系統性的估值體系來了解其內在價值。藥時事 作為擁有超過 35，000 名生醫","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Dcard 原圖：【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點","url":"https://drugnews.com.tw/assets/articles/taipei-biotech-npv-workshop/dcard-01.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/taipei-biotech-npv-workshop/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-06）。【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點。https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-06-taipei-biotech-npv-workshop-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}